Get started
BIOVICA INTERNATIONAL AB SER. BBB

BIOVICA INTERNATIONAL AB SER. B

0.646SEKD
−0.024−3.58%
As of today at 12:59 GMT
SEK
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

BIOVIC_B fundamentals

Key facts

Market capitalization‪148.60 M‬SEK
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−0.88SEK
Founded2008
Employees (FY)26
CEOAnders Rylander
Websitebiovica.com
About

Biovica International AB is engages in the development and commercialization of novel blood-based biomarker assays to improve the monitoring of modern cancer therapies. It offers DiviTum assay, which is intended to monitor and predict treatment response in cancer patients. The company was founded in 2009 and is headquartered in Uppsala, Sweden.

Ownership
‪‪207.36 M‬‬
Free Float shares
‪‪199.03 M‬‬ (95.98%)
Closely held shares
‪‪8.34 M‬‬ (4.02%)
Free Float shares
‪‪199.03 M‬‬ (95.98%)
Closely held shares
‪‪8.34 M‬‬ (4.02%)
Capital structure
Market cap
‪‪148.60 M‬‬
Debt
‪‪4.65 M‬‬
Cash & equivalents
‪‪24.41 M‬‬
Enterprise value
‪‪128.83 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪148.60 M‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
8.24x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
8.24x
Valuation ratios
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪9.00‬
‪18.00‬
‪27.00‬
‪36.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−2,250.00%‬
‪−1,900.00%‬
‪−1,550.00%‬
‪−1,200.00%‬
‪−850.00%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−45.00 M‬‬
‪‪−30.00 M‬‬
‪‪−15.00 M‬‬
‪0.00‬
‪‪15.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−21.00 M‬‬
‪‪−14.00 M‬‬
‪‪−7.00 M‬‬
‪0.00‬
‪‪7.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−21.00 M‬‬
‪‪−14.00 M‬‬
‪‪−7.00 M‬‬
‪0.00‬
‪‪7.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
DiviTum Kits Research Use Only
Tests (In Vitro Diagnostics) - United States
Research Test
DiviTum Kits (In Vitro Diagnostics) - European Union
By country
Period: 2024
United States
Rest of World
European Union

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪1.50 M‬‬
‪‪3.00 M‬‬
‪‪4.50 M‬‬
‪‪6.00 M‬‬
Actual
Estimate
Earnings
Next:Sep 11, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪−0.32‬
‪−0.24‬
‪−0.16‬
‪−0.08‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

No dividends
BIOVIC_B has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−30.00 M‬‬
‪0.00‬
‪‪30.00 M‬‬
‪‪60.00 M‬‬
‪‪90.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪9.00 M‬‬
‪‪18.00 M‬‬
‪‪27.00 M‬‬
‪‪36.00 M‬‬
Assets
Liabilities